Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistPlantacea, LLC dba Kahm was cited for marketing unapproved new drugs containing cannabidiol (CBD) for both human and animal use, including products such as "CBD Hemp Pellets," "K9 Soft Chews," topical gels, creams, and transdermal bands, without FDA approval required under sections 505(a) and 512(a) of the Federal Food, Drug, and Cosmetic Act. The company's animal CBD products were determined to be unsafe new animal drugs, while human CBD products were found to be misbranded drugs lacking required labeling information under section 502(f)(1). The violations were identified through FDA's review of the company's website and social media platforms (Facebook, Instagram, and YouTube) in May 2022, which contained disease claims and therapeutic assertions that established the products as unapproved drugs rather than lawful dietary supplements or cosmetics.